Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 6/20 | 0.35 |
| ▸ | HTR7 | P34969 | 6/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | HTR6 | P50406 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742315 | 0.91 | TP53 (0.43) | TP53ALDH1A1SMN1; SMN2THRBHTT | |
| SCHEMBL30326680 | 0.90 | TP53 (0.35) | TP53ALDH1A1HTR1AHTR7DRD2 | |
| SCHEMBL29603305 | 0.89 | TP53 (0.37) | TP53ALDH1A1SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL15326722 | 0.89 | TP53 (0.42) | TP53ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL23519429 | 0.88 | TP53 (0.37) | TP53ALDH1A1SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL30943672 | 0.87 | KDM4E (0.37) | TP53THRBKMT2AGLA | |
| SCHEMBL31199169 | 0.83 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL17721291 | 0.83 | RARB (0.38) | TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL31083780 | 0.83 | RARB (0.38) | TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL21896456 | 0.83 | RARB (0.38) | TP53ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3100055-A1 | STEPWISE ASSEMBLED CAPTURE COMPOUNDS COMPRISING A CLEAVABLE FUNCTION AND METHOD FOR ISOLATING AND/OR CHARACTERIZING BIOMOLECULES OR BIOMOLECULE FRAGMENTS, IN PARTICULAR PROTEINS OR PROTEIN FRAGMENTS, OF COMPLEX MIXTURES | caprotec bioanalytics GmbH (DE) | 2016-12-07 | — | — | EP | disclosed |
| US-20160349268-A1 | STEPWISE ASSEMBLED CAPTURE COMPOUNDS COMPRISING A CLEAVABLE FUNCTION AND METHOD FOR ISOLATING AND/OR CHARACTERIZING BIOMOLECULES OR BIOMOLECULE FRAGMENTS, IN PARTICULAR PROTEINS OR PROTEIN FRAGMENTS, OF COMPLEX MIXTURES | CAPROTEC BIOANALYTICS GMBH (DE) | 2016-12-01 | — | — | US | disclosed |
| EP-2913674-A1 | Stepwise assembled capture compounds comprising a cleavable function and method for isolating and/or characterizing biomolecules or biomolecule fragments, in particular proteins or protein fragments, of complex mixtures | Caprotec Bioanalytics GmbH (DE) | 2015-09-02 | — | — | EP | disclosed |
| WO-2015114023-A1 | STEPWISE ASSEMBLED CAPTURE COMPOUNDS COMPRISING A CLEAVABLE FUNCTION AND METHOD FOR ISOLATING AND/OR CHARACTERIZING BIOMOLECULES OR BIOMOLECULE FRAGMENTS, IN PARTICULAR PROTEINS OR PROTEIN FRAGMENTS, OF COMPLEX MIXTURES | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160349268-A1 | STEPWISE ASSEMBLED CAPTURE COMPOUNDS COMPRISING A CLEAVABLE FUNCTION AND METHOD FOR ISOLATING AND/OR CHARACTERIZING BIOMOLECULES OR BIOMOLECULE FRAGMENTS, IN PARTICULAR PROTEINS OR PROTEIN FRAGMENTS, OF COMPLEX MIXTURES | FGB, CPB1, FURIN | TP53 617/4885ALDH1A1 4855/4885SMN1; SMN2 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.